You are here

A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing

Last updated on August 9, 2018

FOR MORE INFORMATION
Study Location
Pfizer Investigational Site
Liverpool, , L9 7AL United Kingdom
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Neuralgia, Postherpetic Neuralgia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
18+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Neuropathic pain of peripheral origin as a consequence of either post-herpetic
neuralgia or post-traumatic neuropathic pain

- Well-defined skin area of mechanical allodynia to punctate (von Frey filament) stimuli

- Pain intensity score of ≥ 4/10 for von Frey filament-evoked allodynia at the skin area

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Patients who have undergone neurolytic or neurosurgical therapy, including skin
excisions, for neuropathic pain

- Patients who have trigeminal neuralgia, central pain, chronic radiculopathy, or
peripheral neuropathy of non-mechanical or unknown origin

- Patients with any other co-existing pain which cannot be differentiated from the
neuropathic pain of peripheral origin

NCT00674687
Pfizer
Completed
A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.

Similar Trials

Post-Herpetic Neuralgia
NCT00159666
All Genders
18+
Years
Multiple Sites
Neuralgia
NCT00292188
All Genders
18+
Years
Multiple Sites
Diabetic Neuropathies, Neuralgia
NCT00141219
All Genders
18+
Years
Multiple Sites
A Study Of The Efficacy Of Gabapentin In Neuropathic Pain Patients As Measured By Quantitative Sensory Testing
A Randomized Double-Blind, Placebo-Controlled, Crossover Study To Assess The Reproducibility And The Effect Of Gabapentin On Quantitative Sensory Testing In Neuropathic Pain Patients
The purpose of this study is to assess the reproducibility and the effect of gabapentin on quantitative sensory testing assessments in neuropathic pain subjects.
Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
  • Neuralgia
  • Neuralgia, Postherpetic
  • Drug: 2-weeks placebo then gabapentin
    Placebo for 2 weeks followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 1 week
  • Drug: 1-week placebo then gabapentin
    Placebo for 1 week followed by gabapentin 300 mg oral capsule once daily titrated over 1 week to gabapentin 600 mg three times daily for 2 weeks
  • Placebo Comparator: Sequence 1
    Intervention: Drug: 2-weeks placebo then gabapentin
  • Experimental: Sequence 2
    Intervention: Drug: 1-week placebo then gabapentin
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
23
June 2006
Not Provided

Inclusion Criteria:

  • Neuropathic pain of peripheral origin as a consequence of either post-herpetic neuralgia or post-traumatic neuropathic pain
  • Well-defined skin area of mechanical allodynia to punctate (von Frey filament) stimuli
  • Pain intensity score of ? 4/10 for von Frey filament-evoked allodynia at the skin area

Exclusion Criteria:

  • Patients who have undergone neurolytic or neurosurgical therapy, including skin excisions, for neuropathic pain
  • Patients who have trigeminal neuralgia, central pain, chronic radiculopathy, or peripheral neuropathy of non-mechanical or unknown origin
  • Patients with any other co-existing pain which cannot be differentiated from the neuropathic pain of peripheral origin
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United Kingdom
 
 
NCT00674687
A9451138
No
Not Provided
Not Provided
Director, Clinical Trial Disclosure Group, Pfizer, Inc.
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
May 2008

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now